New to posting not to lurking

Dear Sandtdad,

I just wanted to take a minute and welcome you to the site. My daughter, age 25 has CC too. She also has one big tumor on the right side of her liver and small ones on the left side. She is on gem/cis and 5FU. Her big tumor has shrunk 2 cm. each way so far and her little ones are smaller too. She actually feels better being on the chemo. I hope your treatments keep working and one day you will be able to have surgery. Please visit this site often. The support is awesome. Take care.

-Pam

Hi,
Thanks .
Just a reminder,be always aware of the drug resistance and try to research as much as you can for alternatives.(ie: other molecularly targeted agents). If the tumors shrink enough,consider other options like RFA or radioembo Y90,or chemoembolization. Cat scan or MRI or PET every 3 month to monitor the CC for early treatment options just in case. No more seafood or sushi. Somehow I always suspect seafood is a risk factor for CC.
Keep in touch and I hope we can learn from each other.
God bless you and your family.

Dear sandtdad, welcome to our wonderful family of the most courageous and caring people the world over. Congratulations on seeing some positive gains for yourself against the CC. Attitude plays such an important part. We are happy you found us but sorry you had to. All the research you are doing is the best way to fight CC as knowledge is powerful but unfortunately most of what we know is that we know not much. Please keep us updated on how you are doing as we truly care.

Hi,
Below is a study about GEMOX+cetuximab.
But be careful when you read about the results;it does not provide the long term results of the study eg. drug resistance.

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Dr Birgit Gruenberger MD a Corresponding AuthorEmail Address, Johannes Schueller MD b, Ute Heubrandtner MPharm c, Fritz Wrba MD e, Dietmar Tamandl MD f, Klaus Kaczirek MD f, Rudolf Roka MD d, Sandra Freimann-Pircher MPharm c, Thomas Gruenberger MD f
Summary
Background
Patients with biliary tract cancer have a poor prognosis, and, until recently, no standard palliative chemotherapy has been defined. We aimed to investigate the efficacy and safety of cetuximab in combination with gemcitabine and oxaliplatin (GEMOX) for first-line treatment of biliary tract cancer.
Methods
From Oct 1, 2006, to July 26, 2008, patients with unresectable locally advanced or metastatic biliary tract cancer were sequentially enrolled and treated at one centre in Austria. All patients received intravenous infusions of 500 mg/m2 cetuximab on day 1, 1000 mg/m2 gemcitabine on day 1, and 100 mg/m2 oxaliplatin on day 2, every 2 weeks for 12 cycles. The primary outcome was overall response rate. Analysis was by intention to treat. Adverse reactions were assessed according to National Cancer Institute Common Toxicity Criteria. The study is completed and registered with ClinicalTrials.gov, number NCT01216345.
Findings
30 patients with median age of 68 years (IQR 62—73) were enrolled and included in the analysis. Objective response occurred in 19 patients (63%; 95% CI 56·2—69·, of whom three (10%; 3·2—16· achieved complete response, and 16 (53%; 46·2—59· achieved partial response. Nine patients underwent potentially curative secondary resection after major response to therapy. Grade 3 adverse events were recorded in 13 patients: skin rash (n=4), peripheral neuropathy (n=4), thrombocytopenia (n=3), nausea (n=1), diarrhoea (n=1), and neutropenia (n=1); no grade 4 adverse events were recorded.
Interpretation
Cetuximab plus GEMOX was well tolerated and had encouraging antitumour activity, leading to secondary resection in a third of patients. These findings warrant further study of cetuximab plus GEMOX in a large randomised trial.
God bless

Hi,
Can you tell us what stage and what do you have,intrahepatic CC or extrahepatic CC?
How long have you been on the clinical trial? and
where your are being treated now?

Below are some info with regard to panitumumab and cetuximab,and you may look at GEMOX and cetuximab trials to get some insight into your treatment since the two agents are very similiar but there are more studies done on GEMOX+cetuximab than GEMOX+panitumumab

Two epidermal growth-factor receptor (EGFR)-targeted monoclonal antibodies are currently used as second-line or third-line chemotherapy for metastatic colorectal cancer: cetuximab, an IgG1 chimeric monoclonal antibody, and panitumumab, a fully humanised IgG2 antibody. Preclinical data suggest a similar mode of action for these two drugs.
another source indicated some difference between the mode of action as follows:
Although they both target the EGFR, panitumumab (IgG2) and cetuximab (IgG1) differ in their isotype and they might differ in their mechanism of action. Monoclonal antibodies of the IgG1 isotype may activate the complement pathway and mediate antibody-dependent cellular cytotoxicity (ADCC).[4]
God bless.